meRfi®-GM
Anti-PD-1 antibodies / PD-1 inhibitors
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Anti-PD-1 antibodies / PD-1 inhibitors are drugs that block the T cell checkpoint molecule Programmed cell death protein 1 (PD-1), which is otherwise used by tumors to drive the immune cell to its own death
A discrepancy among the effectiveness of these Anti-PD-1 antibodies / PD-1 inhibitors was observed, as patient response remained as low as 25% in some cases (), which was hypothesized to be associated with the gut microbiome
Anti-PD-1: disease recurrence after response is significant, does not move …
References (Sources)
- Anti-Programmed Death-1-Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing-Therapeutic Benefit to Mice with Established-Tumors
- Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma
- Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors
- Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer
- Patient selection for anti-PD-1/PD-L1 therapy in advanced NSCLC: implications for clinical practice
- PDL-1/PD1 inhibitors: antibody or antinobody?
- Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma